Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma

Table 5

Treatment details of metastatic colorectal cancer patients.

Treatment methods	n (% of 461)	n (any mutation)	n (all wild-type)
Chemotherapy alone	159 (34.5%)	82	77
1 line	21 (4.6%)	15	6
2 lines	79 (17.1%)	52	27
≥3 lines	59 (12.8%)	15	44
Chemotherapy combined with surgery	118 (25.7%)	73	45
Primary lesion resection	63 (13.7%)	36	27
Metastasectomy	22 (4.8%)	16	6
Both	33 (7.2%)	21	12
Chemotherapy combined with radiotherapy	4 (0.8%)	2	2
Chemotherapy combined with targeted therapy	169 (36.6%)	65	104
Bevacizumab therapy	113 (24.5%)	61	52
Anti-EGFR therapy	52 (11.3%)	4	48
Both	4 (0.8%)	0	4
Chemotherapy combined with surgery and targeted therapy (primary lesion resection with anti-EGFR therapy)	2 (0.4%)	0	2
Chemotherapy for the entire population	452 (98.0%)	222	230
1 line	63 (13.7%)	48	15
2 lines	210 (45.5%)	119	91
≥3 lines	179 (38.8%)	55	124